Incyte (INCY) announced that the FDA has approved Monjuvi, tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma, or FL. The Priority Review and FDA approval of the supplemental Biologics License Application for Monjuvi was based on data from the pivotal, randomized, double-blind, placebo-controlled Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi in combination with rituximab and lenalidomide in adult patients with relapsed or refractory FL. Data from the trial was featured in the Late-breaking Session at the 2024 American Society of Hematology Annual Meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- FDA approves Incyte’s tafasitamab-cxix for refractory follicular lymphoma
- Positive Buy Rating for Incyte Driven by Promising INCA33989 Trial Results and Favorable Safety Profile
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Video: Sarepta, Hinge Health among major pre-market movers